Quantcast

Latest Astellas Pharma US Inc. Stories

2014-08-07 23:10:49

The Corporate Whistleblower Center is urging physicians or pharmaceutical company insiders to consider becoming a whistleblower, and a recipient of what could be a substantial reward, provided they have well documented proof of a drug company promoting off-labeled drugs that have not been approved by the FDA. For more information about federal whistleblower programs, potential healthcare whistleblowers are always welcome to call the Corporate Whistleblower Center anytime at 866-714-6466....

2014-07-15 08:29:02

WASHINGTON, July 15, 2014 /PRNewswire/ -- The Corporate Whistleblower Center is urging a medical doctor, or pharmaceutical company insider to call them at 866-714-6466, if they have well documented proof a drug company is involved in an off labeling scheme that results in Medicare being overbilled, because the rewards for this type of information really can be substantial. http://CorporateWhistleblowerCenter.Com Photo - http://photos.prnewswire.com/prnh/20140714/126736 Photo -...

2014-06-11 08:30:30

Special Patient-Focused Event Kicks Off Astellas' Fifth Annual Changing Tomorrow Day Initiative KISSIMMEE, Fla., June 11, 2014 /PRNewswire/ -- About 1,400 Astellas Pharma employees will be descending on Give Kids The World (GKTW) for the second time to tackle projects ranging from landscaping to assembling furniture as well as resurfacing parking lots and roads. This year, Astellas is bringing an even bigger volunteer group than the record-breaking Astellas team that volunteered in...

2014-06-04 23:15:16

The Corporate Whistleblower Center cannot emphasize enough how huge of a problem off-labeling drugs is, and the potential for rewards for information related to this type of Medicare fraud can be substantial as indicated by a recent Justice Department settlement. Pharmaceutical sales reps, managers, or employees are urged to call the Whistleblower Center anytime at 866-714-6466, if they possess well documented proof of this type of activity. http://CorporateWhistleblowerCenter.Com...

2014-06-01 08:20:11

-Study appears in June 1 online edition- NORTHBROOK, Ill. and SAN FRANCISCO, JUNE 1, 2014 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc. (Nasdaq: MDVN) today announced the online publication in the New England Journal of Medicine of the results from the Phase 3 PREVAIL trial, an international, randomized, double-blind, placebo-controlled clinical study of enzalutamide. The study evaluated the benefit...

2014-05-14 16:29:25

Eight abstracts will highlight enzalutamide studies in prostate and breast cancers NORTHBROOK, Ill. and SAN FRANCISCO, May 14, 2014 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc. (Nasdaq: MDVN) announced that eight enzalutamide abstracts will be presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30-June 3 in Chicago. http://photos.prnewswire.com/prnvar/20140416/84970 The...

2014-04-16 12:31:30

NORTHBROOK, Ill., April 16, 2014 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that it has reached an agreement with the U.S. Department of Justice to resolve civil claims regarding the marketing of MYCAMINE(®) (micafungin sodium) for injection. Under the agreement, Astellas will pay $7.3 million to the settling parties. The Department of Justice had investigated Astellas for alleged off-label...

2014-04-15 08:31:27

NEW YORK, April 15, 2014 /PRNewswire-USNewswire/ -- The National Kidney Foundation (NKF) announced today, during National Donate Life Month, that Astellas Pharma US, Inc. was named the first-ever National Presenting Sponsor for the Kidney Walk. Through this partnership, Astellas will support more than 85 Kidney Walk events being held in major cities across the country. "Our partnership with NKF exemplifies what Astellas and these walks are all about - enabling patients to be their own...

2014-04-03 08:28:53

TOKYO and SAN FRANCISCO, April 3, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503) and Medivation Inc. (NASDAQ: MDVN) today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI(®) (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet...

2014-02-28 08:24:51

TOKYO, Feb. 28, 2014 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo:4503, "Astellas") announced today that the company has amended the License, Co-Development and Co-Promotion Agreement on isavuconazole under co-development with Basilea Pharmaceutica Ltd. ("Basilea"). Based on this amendment, the territories subject to the License Agreement have been changed to reflect that Astellas will be responsible for all regulatory filings and will exclusively commercialize and assume full...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related